[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75968]], camposKey:2076-3921 2022-11-01 Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68523]], camposKey:0269-2813 2021-05-01 Effectiveness and safety of methotrexate monotherapy in patients with Crohn¿s disease refractory to anti-TNF-¿: results from the ENEIDA registry10211029, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68524]], camposKey:0269-2813 2020-09-01 Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry10171030, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65152]], camposKey:1355-008X 2020-06-01 Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor557563, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52747]], camposKey:1078-0998 2020-01-01 Different Intraepithelial CD3+ Cell Numbers in Crohn's Disease and Ulcerative Colitis00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66448]], camposKey:1130-0108 2020-01-01 Endoscopic ultrasound-guided fine-needle aspiration for splenomegaly and focal splenic lesion: Is it safe, effective and necessary? ORIGINAL PAPERS355359, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49514]], camposKey:1438-2377 2019-08-01 Selection of the most suitable mixture of flours and starches for the improvement of gluten-free breads through their volatile profiles17551766, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56281]], camposKey:1873-9946 2019-01-01 Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study14921500, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=68525]], camposKey:1130-0108 2019-01-01 Comparative study of overweight and obese patients with nonalcoholic fatty liver disease256263, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54068]], camposKey:2444-8818 2019-01-01 Optimization and validation of GC/MS methods for trace analysis of VOCs and pesticides in water2124, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56393]], camposKey:0269-2813 2019-01-01 Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry278288, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=37414]], camposKey:0963-9969 2018-01-01 Analysis of volatile compounds in gluten-free bread crusts with an optimised and validated SPME-GC/QTOF methodology686695, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49525]], camposKey:0308-8146 2018-01-01 Extruded flour improves batter pick-up, coating crispness and aroma profile106114][][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64252]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64252]]][][][][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@480484bc, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1299c85, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@641f9979, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1e4e792b][][][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=60749]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=60749]]][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@464881], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5bb9f4], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4689a6]][][][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@17554][]
